XML 64 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Share equity incentive plans (Tables)
 12 Months Ended
Dec. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of options activity
The following table summarizes share option activity for the years ended December 31, 2021 and 2022:
December 31,
20212022
Number
of
Options		Weighted-Average Exercise PriceWeighted-
Average remaining Contractual Term
(in years)		Number
of
Options		Weighted-Average Exercise PriceWeighted-
Average remaining Contractual Term
(in years)
Outstanding at the beginning of the year9,874,165 $1.99 6.839,981,394 $2.37 6.65
Granted1,708,500 3.71 — — — — 
Exercised(1,301,233)0.94 — (911,307)2.23 — 
Forfeited(300,038)3.71 — (707,157)3.56 — 
Outstanding at the end of the year9,981,394 $2.37 6.658,362,930 $2.28 5.25
Exercisable at the end of the year6,150,329 $1.99 5.547,001,928 $2.18 4.75
Schedule of valuation assumptions
The fair value of the share options granted in the year ended December 31, 2021 was estimated on the grant date based on the following assumptions:
Volatility60%
Expected term in years6.25
Risk-free interest rate
0.55% - 0.92%
Estimated fair value of underlying ordinary shares
12.92 - 24.08
Dividend yield0%
Schedule of options by exercise price
The following table summarizes information about share options outstanding under the 2012 Plan and 2021 Plan as of December 31, 2021 and 2022:
Options OutstandingOptions Exercisable
Number Outstanding at December 31, 2021Weighted Average Remaining Contractual Life (Years)Number Exercisable at December 31, 2021Weighted Average Remaining Contractual Life (Years)
$0.000389,000 1.5889,000 1.58
$0.01355,700 8.85155,618 8.85
$0.401,149,241 2.051,149,241 2.05
$0.6065,286 3.4565,286 3.45
$1.43401,500 8.71125,468 8.71
$1.90594,320 3.73594,320 3.73
$2.171,396,871 6.151,235,090 6.12
$2.25117,224 3.24117,224 3.24
$2.388489,700 8.69129,400 8.19
$2.712,655,489 6.851,936,746 6.76
$3.041,401,700 9.08131,250 9.08
$3.44248,501 7.36140,191 6.98
$3.57748,562 8.60261,308 8.54
$5.9779,500 8.9120,187 8.91
$7.60184,800 9.08— 0
$24.084,000 9.61— 0
Total9,981,394 6.656,150,329 5.54
Aggregate intrinsic value$155,136 $97,907 
Options OutstandingOptions Exercisable
Number Outstanding at December 31, 2022Weighted Average Remaining Contractual Life (Years)Number Exercisable at December 31, 2022Weighted Average Remaining Contractual Life (Years)
$0.000389,000 0.5889,000 0.58
$0.01355,700 7.85244,543 7.85
$0.401,078,500 1.121,078,500 1.12
$0.6031,046 1.8631,046 1.86
$1.43381,000 7.62211,468 7.55
$1.90565,320 2.81565,320 2.81
$2.17975,288 5.03975,288 5.03
$2.2557,394 3.5357,394 3.53
$2.388387,750 7.77195,900 7.68
$2.712,331,732 5.682,259,187 5.67
$3.041,282,648 7.94647,691 7.81
$3.44204,394 6.80162,650 6.78
$3.57432,000 1.93394,841 1.43
$5.9750,000 7.9325,312 7.93
$7.60141,158 7.8563,788 7.56
Total8,362,930 5.257,001,928 4.75
Aggregate intrinsic value$34,860 $29,858 
Schedule of RSU activity
The following table summarizes RSU (including PRSU) activity for the years ended December 31, 2021 and 2022:
December 31,
2021		The weighted average fair value at grant dateDecember 31,
2022		The weighted average fair value at grant date
Outstanding at the beginning of the year132,500 $7.60 967,797 $18.97 
Granted880,022 20.41 2,678,036 10.66 
Vested(10,354)11.15 (319,516)17.91 
Forfeited(34,371)14.46 (459,337)15.06 
Outstanding at the end of the year967,797 18.97 2,866,980 12.06 
Unvested RSUs967,797 18.97 2,866,980 12.06 
Schedule of expenses capitalized
The following table summarizes the share-based compensation recorded in each line item in the accompanying consolidated statements of comprehensive income (loss):
Year Ended December 31,
202020212022
Cost of revenue$40 $211 $599 
Research and development1,107 4,058 5,287 
Sales and marketing821 3,450 5,995 
General and administrative2,832 3,452 5,106 
Total$4,800 $11,171 $16,987